Mergers & Acquisitions ·
Catalyst Pharmaceuticals, Inc. stockholders at a special meeting held on July 8, 2026, approved the merger proposal to…
CPRXCatalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. stockholders at a special meeting held on July 8, 2026, approved the merger proposal to be acquired by Angelini Pharma S.p.A. and its subsidiary, Angelini Cielo Inc. While the merger proposal was approved by a majority of outstanding shares, the non-binding advisory compensation proposal was rejected by stockholders. All current directors are expected to resign upon the effective time of the merger. Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of rare neuromuscular diseases.